inhibitory glp 1 Comparison of GLP-1 receptor agonists and DPP-4 inhibitors GLP-1 Receptor Agonists as Treatments

A 2024 survey of 340 obesity medicine specialists (Fitch et al., Obesity Science & Practice ) found that 68% restart at 2.5 mg, 24% start at 5 mg, and 8% individualize based on patient history

Moreover, because these drugs are already approved for other uses, such as diabetes and weight management, they may be a safer and faster alternative to developing entirely new addiction treatments

Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer

Stress-driven eating, even when appetite is suppressed by cagrilintide, can undermine caloric deficits

Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinsons disease